Abstract:Background and purpose: The pathophysiological features of acute ischemic stroke (AIS) often involve dysfunction of the blood-brain barrier (BBB), characterized by the degradation of tight junction proteins (Tjs) leading to increased permeability. This dysfunction can exacerbate cerebral injury and contribute to severe complications. The permeability of the BBB fluctuates during different stages of AIS and is influenced by various factors. Developing effective therapies to restore BBB function remains a significant challenge in AIS treatment. High levels of vascular endothelial growth factor (VEGF) in the early stages of AIS have been shown to worsen BBB breakdown and stroke progression. Our study aimed to investigate the protective effects of the VEGF receptor inhibitor Axitinib on BBB dysfunction and cerebral ischemia/reperfusion-induced injury. Methods: BEnd3 cell exposed to oxygen-glucose deprivation (OGD) model was constructed to estimate pharmacological activity of Axitinib (400 ng/ml) on anti-apoptosis and pathological barrier function recovery. In vivo, rats were subjected to a 1 h transient middle cerebral artery occlusion and 23 h reperfusion (tMCAO/R) to investigate the permeability of BBB and cerebral tissue damage. Axitinib was administered through the tail vein at the beginning of reperfusion. BBB integrity was assessed by Evans blue leakage and the expression levels of Tjs claudin-5 and occludin. Results: Our research revealed that co-incubation with Axitinib enhanced the cell viability of OGD-insulted bEnd3 cells, decreased LDH leakage rate, and suppressed the expression of apoptosis-related proteins cytochrome C and Bax. Axitinib also mitigated the damage to Tjs and facilitated the restoration of transepithelial electrical resistance in OGD-insulted bEnd.3 cells. In vivo, Axitinib administration reduced intracerebral Evans blue leakage and up-regulated the expression of Tjs in the penumbra brain tissue in tMCAO/R rats. Notably, 10 mg/kg Axitinib exerted a significant anti-ischemic effect by decreasing cerebral infarct volume and brain edema volume, improving neurological function, and reducing pro-inflammatory cytokines IL-6 and TNF-alpha in the brain. Conclusions: Our study highlights Axitinib as a potent protectant of blood-brain barrier function, capable of promoting pathological blood-brain barrier recovery through VEGF inhibition and increased expression of tight junction proteins in AIS. This suggests that VEGF antagonism within the first 24 h post-stroke could be a novel therapeutic approach to enhance blood-brain barrier function and mitigate ischemia-reperfusion injury.

[Vasoactive Intestinal Peptide Enhances Angiogenesis after Focal Cerebral Ischemia].

Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis.

Endothelial Protection of Vasoactive Intestinal Peptide Enhances Angiogenesis Mediated by eNOS Pathway Following Focal Cerebral Ischemia in Rats

Vasoactive intestinal peptide administration after stroke in rats enhances neurogenesis and improves neurological function

[Neuroprotective Effects of Vasoactive Intestinal Peptide Against Rat Cerebral Ischemia].

Effects of vasoactive intestinal peptide on the infarct volume in rat transient focal cerebral Ischemia

Vasoactive Intestinal Peptide Attenuates Liver Ischemia/reperfusion Injury in Mice Via the Cyclic Adenosine Monophosphate-Protein Kinase a Pathway.

Effect of vasoactive intestinal peptide on S100β in serum in rat transient focal cerebral ischemia

Protection of Vasoactive Intestinal Peptide on the Blood-Brain Barrier Dysfunction Induced by Focal Cerebral Ischemia in Rats

VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia

Experimental Research on the Effect of VEGF on Angiogenesis in Focal Cerebral Ischemia

Intranasal Administration of VEGF with Effect on Angiogenesis in Infarction Boundary Zones in Rats with Cerebral Ischemia

VEGF Promotes Angiogenesis and Functional Recovery in Stroke Rats.

The Protective Effects of Axitinib on Blood-Brain Barrier Dysfunction and Ischemia-Reperfusion Injury in Acute Ischemic Stroke

Effects of angiopoietin-1 on vascular endothelial growth factor-induced angiogenesis in the mouse brain.

Enhanced Angiogenesis with Dl-3N-butylphthalide Treatment after Focal Cerebral Ischemia in RHRSP

The novel VEGF receptor antagonist, VGA1155, reduces edema, decreases infarct and improves neurological function after stroke in rats

Intraventricular Injection of Liposome-Mediated VEGF Plasmids Enhances Brain Repair Following Ischemia-Reperfusion Injury

Intraventricular Vascular Endothelial Growth Factor Antibody Increases Infarct Volume Following Transient Cerebral Ischemia.

Abstract 3302: Vascular Endothelial Growth Factor Receptor Inhibition Impairs Intracerebral Hemorrhage-induced Angiogenesis

Neuroprotective Effect of VEGF/VEGFR in Cerebral Ischemia Reperfusion Injury